Director Barry J. Simon disposed of 75,000 shares of ImmunityBio, Inc. (NASDAQ: IBRX) on February 24, 2026, executing the sale at a weighted average price of $12.0105. The reported price range for the transaction was $12.00 to $12.025, producing a total transaction value of $900,787.
Following that sale, Simon's direct holdings in ImmunityBio stand at 2,850,821 shares. The sale was carried out under a pre-established Rule 10b5-1 trading plan that the director adopted on September 4, 2024.
Since the transaction, the company's share price has declined to $9.55. The stock is trading below its 52-week high of $12.43 but remains well above its 52-week low of $1.83.
On fundamental measures, ImmunityBio is presented with specific financial metrics included in company reporting: a market valuation of $9.71 billion, revenue of $113.29 million, and a gross profit margin of 99.34%.
Market research notes referenced in company communications indicate analysts expect sales growth for the current year, though the company is not anticipated to be profitable in the near term. Investors are pointed to InvestingPro Tips for additional context; the company notes that there are 11 more InvestingPro Tips available for deeper analysis of IBRX's financial position and growth outlook.
ImmunityBio also disclosed operational and commercial developments tied to its oncology product ANKTIVA. The company reported that ANKTIVA generated $113 million in revenue for 2025, a year-over-year increase of 700% compared with 2024. Unit volumes for ANKTIVA rose to 3,745 in 2025, representing a 750% increase from the prior year.
On the clinical front, ImmunityBio completed enrollment in a Phase 2 trial evaluating ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) for bladder cancer. The company reported that interim analysis of the trial demonstrated statistically significant improvements in response duration.
Commercial expansion efforts include a distribution agreement with Accord Healthcare to supply ANKTIVA across 30 European countries. The company has also formed partnerships with Biopharma and Cigalah Healthcare to introduce ANKTIVA in Saudi Arabia and the wider Middle East and North Africa region.
Following these developments and the product's commercial progress, H.C. Wainwright raised its price target for ImmunityBio to $15 while maintaining a Buy rating. The firm cited the company's successful U.S. launch and European Union approval of ANKTIVA in its rationale.
Taken together, the insider sale and the company's recent operational and commercial announcements provide contemporaneous signals for investors to weigh. The sale was executed under a pre-set trading plan, and the company continues to report strong ANKTIVA revenue growth, increasing unit sales, expanded distribution channels, and positive interim clinical results.